Abstract
Background: Although haemorrhage is a major cause of morbidity and mortality in liver surgery, there is very little available guidance on its management. Methods: The aim of this study was to identify current practice in the UK in this regard. An online survey was created and hepatobiliary (HPB) specialists who were members of a specialist society and others who were known practitioners were invited by e-mail to complete the survey anonymously. Results: Fifty-one percent responded (n = 36/70), and most of these respondents worked at large HPB centres (>100 liver resections/year; n = 24, 66%). Not all questionnaires were fully completed by the individual surgeons. Thirty-eight percent of the surgeons routinely used Pringle's manoeuvre. Most surgeons used ligation of the inflow vessels (n = 16, 44%) and stapled the outflow vessels (n = 15, 42%). The Cavitron ultrasonic surgical aspirator (CUSA; 54%, 13/24) was preferred for parenchymal transection. The majority routinely used haemostatic adjuncts (n = 22, 62%), whilst 33% (n = 12) used them occasionally. Twenty-three (64%) felt manufactured haemostatic adjuncts played a major role in maintaining haemostasis and 19 preferred fibrin-based products. Conclusion: The Pringle manoeuvre is a popular technique amongst specialist UK liver surgeons and the CUSA is used by nearly half of the surgeons. Despite the absence of definitive evidence for their benefit, manufactured haemostatic adjuncts are still widely used, especially the fibrin-based adjuncts.
References
1.
Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, et al: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002;236:397-406, discussion 406-407.
2.
Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, et al: Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1,222 consecutive patients from a prospective database. Ann Surg 2004;240:698-708, discussion 708-710.
3.
Cockbain AJ, Masudi T, Lodge JP, Toogood GJ, Prasad KR: Predictors of blood transfusion requirement in elective liver resection. HPB (Oxford) 2010;12:50-55.
4.
Sima CS, Jarnagin WR, Fong Y, Elkin E, Fischer M, Wuest D, et al: Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg 2009;250:914-921.
5.
Tralhao JG, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D: Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007;54:1200-1206.
6.
Kooby DA, Stockman J, Ben-Porat L, Gonen M, Jarnagin WR, Dematteo RP, et al: Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg 2003;237:860-869, discussion 869-870.
7.
Stephenson KR, Steinberg SM, Hughes KS, Vetto JT, Sugarbaker PH, Chang AE: Perioperative blood transfusions are associated with decreased time to recurrence and decreased survival after resection of colorectal liver metastases. Ann Surg 1988;208:679-687.
8.
Heaton N: Advances and methods in liver surgery: haemostasis. Eur J Gastroenterol Hepatol 2005;17(suppl 1):S3-S12.
9.
Palavecino M, Kishi Y, Chun YS, Brown DL, Gottumukkala VN, Lichtiger B, et al: Two-surgeon technique of parenchymal transection contributes to reduced transfusion rate in patients undergoing major hepatectomy: analysis of 1,557 consecutive liver resections. Surgery 2010;147:40-48.
10.
Gohel MS, Bulbulia RA, Slim FJ, Poskitt KR, Whyman MR: How to approach major surgery where patients refuse blood transfusion (including Jehovah's Witnesses). Ann R Coll Surg Engl 2005;87:3-14.
11.
Darwish A: Liver transplant in Jehovah's Witnesses patients. Curr Opin Organ Transplant 2011;16:326-330.
12.
Jabbour N, Gagandeep S, Mateo R, Sher L, Strum E, Donovan J, et al: Live donor liver transplantation without blood products: strategies developed for Jehovah's Witnesses offer broad application. Ann Surg 2004;240:350-357.
13.
Petrowsky H, Gonen M, Jarnagin W, Lorenz M, DeMatteo R, Heinrich S, et al: Second liver resections are safe and effective treatment for recurrent hepatic metastases from colorectal cancer: a bi-institutional analysis. Ann Surg 2002;235:863-871.
14.
Abu Hilal M, Underwood T, Taylor MG, Hamdan K, Elberm H, Pearce NW: Bleeding and hemostasis in laparoscopic liver surgery. Surg Endosc 2010;24:572-577.
15.
Saif R, Jacob M, Robinson S, Amer A, Kei-Hui D, Sen G, et al: Use of fibrin-based sealants and gelatin-matrix hemostats in laparoscopic liver surgery. Surg Laparosc Endosc Percutan Tech 2011;21:131-141.
16.
van der Bilt JD, Livestro DP, Borren A, van Hillegersberg R, Borel Rinkes IH: European survey on the application of vascular clamping in liver surgery. Dig Surg 2007;24:423-435.
17.
Pringle J: Notes on the arrest of hepatic haemorrhage due to trauma. Ann Surg 1909;48:6.
18.
Man K, Fan ST, Ng IO, Lo CM, Liu CL, Yu WC, et al: Tolerance of the liver to intermittent Pringle maneuver in hepatectomy for liver tumors. Arch Surg 1999;134:533-539.
19.
Torzilli G, Procopio F, Donadon M, Del Fabbro D, Cimino M, Montorsi M: Safety of intermittent Pringle maneuver cumulative time exceeding 120 min in liver resection: a further step in favor of the ‘radical but conservative' policy. Ann Surg 2012;255:270-280.
20.
Makuuchi M, Mori T, Gunven P, Yamazaki S, Hasegawa H: Safety of hemihepatic vascular occlusion during resection of the liver. Surg Gynecol Obstet 1987;164:155-158.
21.
Wang HQ, Yang JY, Yan LN: Hemihepatic versus total hepatic inflow occlusion during hepatectomy: a systematic review and meta-analysis. World J Gastroenterol 2011;17:3158-3164.
22.
Figueras J, Llado L, Ruiz D, Ramos E, Busquets J, Rafecas A, et al: Complete versus selective portal triad clamping for minor liver resections: a prospective randomized trial. Ann Surg 2005;241:582-590.
23.
Horgan PG, Leen E: A simple technique for vascular control during hepatectomy: the half-Pringle. Am J Surg 2001;182:265-267.
24.
Rahbari NN, Wente MN, Schemmer P, Diener MK, Hoffmann K, Motschall E, et al: Systematic review and meta-analysis of the effect of portal triad clamping on outcome after hepatic resection. Br J Surg 2008;95:424-432.
25.
Nakajima Y, Shimamura T, Kamiyama T, Matsushita M, Sato N, Todo S: Control of intraoperative bleeding during liver resection: analysis of a questionnaire sent to 231 Japanese hospitals. Surg Today 2002;32:48-52.
26.
Gurusamy KS, Kumar Y, Ramamoorthy R, Sharma D, Davidson BR: Vascular occlusion for elective liver resections. Cochrane Database Syst Rev 2009;1:CD007530.
27.
Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR: Methods of vascular occlusion for elective liver resections. Cochrane Database Syst Rev 2009;1:CD007632.
28.
Hoekstra LT, van Trigt JD, Reiniers MJ, Busch OR, Gouma DJ, van Gulik TM: Vascular occlusion or not during liver resection: the continuing story. Dig Surg 2012;29:35-42.
29.
Abdalla EK, Noun R, Belghiti J: Hepatic vascular occlusion: which technique? Surg Clin North Am 2004;84:563-585.
30.
Zhang J, Lai EC, Zhou WP, Fu S, Pan Z, Yang Y, et al: Selective hepatic vascular exclusion versus Pringle manoeuvre in liver resection for tumours encroaching on major hepatic veins. Br J Surg 2012;99:973-977.
31.
Rahbari NN, Koch M, Mehrabi A, Weidmann K, Motschall E, Kahlert C, et al: Portal triad clamping versus vascular exclusion for vascular control during hepatic resection: a systematic review and meta-analysis. J Gastrointest Surg 2009;13:558-568.
32.
Belghiti J, Noun R, Zante E, Ballet T, Sauvanet A: Portal triad clamping or hepatic vascular exclusion for major liver resection. A controlled study. Ann Surg 1996;224:155-161.
33.
Lin T, Tsu K, Mien C, Chen C: Study on Lobectomy of liver. J Formos Med Assoc 1958;57:8.
34.
Baer HU, Gilg M, Maddern GJ, Blumgart LH: High velocity water jet dissection in liver surgery (in German). Helv Chir Acta 1992;59:437-442.
35.
Rau HG, Meyer G, Jauch KW, Cohnert TU, Buttler E, Schildberg FW: Liver resection with the water jet: conventional and laparoscopic surgery (in German). Chirurg 1996;67:546-551.
36.
Takayama T, Makuuchi M, Kubota K, Harihara Y, Hui AM, Sano K, et al: Randomized comparison of ultrasonic versus clamp transection of the liver. Arch Surg 2001;136:922-928.
37.
Campagnacci R, De Sanctis A, Baldarelli M, Di Emiddio M, Organetti L, Nisi M, et al: Hepatic resections by means of electrothermal bipolar vessel device (EBVS) LigaSure V: early experience. Surg Endosc 2007;21:2280-2284.
38.
Gertsch P, Pelloni A, Guerra A, Krpo A: Initial experience with the harmonic scalpel in liver surgery. Hepatogastroenterology 2000;47:763-766.
39.
Arita J, Hasegawa K, Kokudo N, Sano K, Sugawara Y, Makuuchi M: Randomized clinical trial of the effect of a saline-linked radiofrequency coagulator on blood loss during hepatic resection. Br J Surg 2005;92:954-959.
40.
Zhang S, Zheng Y, Wu B, Ji S, Yu Z, Zhang Q: Is the TissueLink dissecting sealer a better liver resection device than clamp-crushing? A meta-analysis and system review. Hepatogastroenterology 2012;59:2602-2608.
41.
Balaa FK, Gamblin TC, Tsung A, Marsh JW, Geller DA: Right hepatic lobectomy using the staple technique in 101 patients. J Gastrointest Surg 2008;12:338-343.
42.
Aldrighetti L, Pulitano C, Arru M, Catena M, Finazzi R, Ferla G: ‘Technological' approach versus clamp crushing technique for hepatic parenchymal transection: a comparative study. J Gastrointest Surg 2006;10:974-979.
43.
Lesurtel M, Selzner M, Petrowsky H, McCormack L, Clavien PA: How should transection of the liver be performed?: a prospective randomized study in 100 consecutive patients: comparing four different transection strategies. Ann Surg 2005;242:814-822, discussion 822-823.
44.
Gurusamy KS, Pamecha V, Sharma D, Davidson BR: Techniques for liver parenchymal transection in liver resection. Cochrane Database Syst Rev 2009;1:CD006880.
45.
Alfieri S, Micelli DD, Ridolfini M, Rotundi F, Giorgio AD, Limongelli F, et al: The role of oxidized regenerated cellulose in preventing surgical site infections: a randomized prospective study on 49 patients with ‘dirty' surgical wounds. Osp Ital Chir 2007;13:8.
46.
Seyednejad H, Imani M, Jamieson T, Seifalian AM: Topical haemostatic agents. Br J Surg 2008;95:1197-1225.
47.
Noun R, Elias D, Balladur P, Bismuth H, Parc R, Lasser P, et al: Fibrin glue effectiveness and tolerance after elective liver resection: a randomized trial. Hepatogastroenterology 1996;43:221-224.
48.
Chapman WC, Clavien PA, Fung J, Khanna A, Bonham A: Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg 2000;135:1200-1204, discussion 1205.
49.
Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, et al: Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg 2004;139:1148-1154.
50.
Frilling A, Stavrou GA, Mischinger HJ, de Hemptinne B, Rokkjaer M, Klempnauer J, et al: Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg 2005;390:114-120.
51.
Liu M, Lui WY: The use of fibrin adhesive for hemostasis after liver resection. Zhonghua Yi Xue Za Zhi (Taipei) 1993;51:19-22.
52.
Eder F, Meyer F, Nestler G, Halloul Z, Lippert H: Sealing of the hepatic resection area using fibrin glue reduces significant amount of postoperative drain fluid. World J Gastroenterol 2005;11:5984-5987.
53.
Kohno H, Nagasue N, Chang YC, Taniura H, Yamanoi A, Nakamura T: Comparison of topical hemostatic agents in elective hepatic resection: a clinical prospective randomized trial. World J Surg 1992;16:966-969, discussion 970.
54.
Briceno J, Naranjo A, Ciria R, Diaz-Nieto R, Sanchez-Hidalgo JM, Luque A, et al: A prospective study of the efficacy of clinical application of a new carrier-bound fibrin sealant after liver resection. Arch Surg 2010;145:482-488.
55.
Figueras J, Llado L, Miro M, Ramos E, Torras J, Fabregat J, et al: Application of fibrin glue sealant after hepatectomy does not seem justified: results of a randomized study in 300 patients. Ann Surg 2007;245:536-542.
56.
Berrevoet F, de Hemptinne B: Clinical application of topical sealants in liver surgery: does it work? Acta Chir Belg 2007;107:504-507.
57.
de Boer MT, Boonstra EA, Lisman T, Porte RJ: Role of fibrin sealants in liver surgery. Dig Surg 2012;29:54-61.
58.
Boonstra EA, Molenaar IQ, Porte RJ, de Boer MT: Topical haemostatic agents in liver surgery: do we need them? HPB (Oxford) 2009;11:306-310.
59.
Boonstra E, Adelmeijer J, Verkade H, Boer Md, Porte R, Lisman T: Fibrinolytic proteins in human bile accelerate lysis of plasma clots and induce breakdown of fibrin sealants. Ann Surg 2012;256:306-312.
60.
Horowitz B, Busch M: Estimating the pathogen safety of manufactured human plasma products: application to fibrin sealants and to thrombin. Transfusion 2008;48:1739-1753.
61.
Hino M, Ishiko O, Honda KI, Yamane T, Ohta K, Takubo T, et al: Transmission of symptomatic parvovirus B19 infection by fibrin sealant used during surgery. Br J Haematol 2000;108:194-195.
62.
Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW: Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004;18:349-351.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
